Local immunomodulation for cancer therapy: Providing treatment where needed

Marieke F. Fransen; Ferry Ossendorp; Ramon Arens; Cornelis J. M. Melief

doi:10.4161/onci.26493

Local immunomodulation for cancer therapy: Providing treatment where needed

Marieke F. Fransen, Ferry Ossendorp, Ramon Arens, Cornelis J. M. Melief

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy. © 2013 Landes Bioscience.

Original language	English
Article number	e26493
Journal	OncoImmunology
Volume	2
Issue number	11
DOIs	https://doi.org/10.4161/onci.26493
Publication status	Published - 2013
Externally published	Yes

Access to Document

10.4161/onci.26493

Cite this

@article{a529cddbbc6541588bcde4f7d6da058a,

title = "Local immunomodulation for cancer therapy: Providing treatment where needed",

abstract = "In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy. {\textcopyright} 2013 Landes Bioscience.",

author = "Fransen, {Marieke F.} and Ferry Ossendorp and Ramon Arens and Melief, {Cornelis J. M.}",

year = "2013",

doi = "10.4161/onci.26493",

language = "English",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "11",

}

TY - JOUR

T1 - Local immunomodulation for cancer therapy: Providing treatment where needed

AU - Fransen, Marieke F.

AU - Ossendorp, Ferry

AU - Arens, Ramon

AU - Melief, Cornelis J. M.

PY - 2013

Y1 - 2013

N2 - In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy. © 2013 Landes Bioscience.

AB - In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy. © 2013 Landes Bioscience.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84892421320&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/24490127

U2 - 10.4161/onci.26493

DO - 10.4161/onci.26493

M3 - Article

C2 - 24490127

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 11

M1 - e26493

ER -

Local immunomodulation for cancer therapy: Providing treatment where needed

Abstract

Access to Document

Other files and links

Cite this